Amgen (NASDAQ:AMGN) executives highlighted broad-based growth in 2025 and laid out expectations for continued momentum in ...

Although the revenue and EPS for Amgen (AMGN) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street ...

Amgen Inc. ( AMGN) Q4 2025 Earnings Call February 3, 2026 4:30 PM EST ...

Amgen is running a number of studies of its obesity drug, MariTide.

By Deena Beasley Feb 3 (Reuters) - Amgen on Tuesday reported fourth-quarter financial results that came in ahead of Wall ...

Analysts expect the company to post earnings of $4.76, representing a 10.4% drop from the corresponding period of the ...

Amgen Inc. (NASDAQ:AMGN) is one of the stocks on Jim Cramer’s recent game plan. Cramer said that he heard good things about the company during the JPMorgan Healthcare Conference, as he commented: With ...

Amgen Inc. reports fourth-quarter earnings today after the bell, putting the spotlight on how the $185.6 billion biotechnology giant plans to navigate a year marked by significant biosimilar ...

In its upcoming report, Amgen (AMGN) is predicted by Wall Street analysts to post quarterly earnings of $4.74 per share, reflecting a decline of 10.7% compared to the same period last year. Revenues ...

AMGN stock is in focus ahead of Q4 earnings, with biosimilar pressure and newer drug growth shaping expectations for the ...

Looking ahead, Amgen issued 2026 guidance with revenue projected between $37.0 billion and $38.4 billion, compared to the consensus estimate of $37.1 billion. The company expects adjusted EPS of ...

An updated edition of the December 16, 2025, article. An aging U.S. population is becoming a first-order driver of consumption reallocation. Going by the data from the United States Census Bureau, by ...